EdiGene, Inc., a Beijing, China-based developer of genome editing technologies to accelerate drug discovery and develop novel therapeutics for a broad range of diseases, completed an RMB 450 million (approximately USD 67 million) Series B financing.
The round was led by 3H Health Investment with participation from Sequoia Capital China, Alwin Capital and Kunlun Capital, along with continued support by previous investors, including IDG Capital, Lilly Asia Venture, Huagai Capital and Green Pine Capital Partners.
Proceeds from the financing will be used to advance the company’s pipeline into clinics and to expand the team.
Founded in 2015 and led by Dong Wei, Ph.D., CEO, and Wensheng Wei, Scientific Founder, EdiGene is a biotechnology company focused on leveraging genome editing technologies to accelerate drug discovery and develop novel therapeutics for a broad range of genetic diseases and cancer.
The company has established four gene editing based platforms and is advancing its early stage programs into clinical development for patients with genetic diseases and cancer. The four platforms are ex vivo genome-editing platforms for hematopoietic stem cells and T cells, in vivo therapeutic platform based on RNA base editing, and high-throughput genome-editing screening to discover novel targeted therapies.
EdiGene has subsidiaries in Guangzhou, China and Cambridge, Massachusetts, USA.